Vistin Pharma ASA
OSE:VISTN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (10.6), the stock would be worth kr27.99 (23% upside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 8.6 | kr22.7 |
0%
|
| 3-Year Average | 10.6 | kr27.99 |
+23%
|
| 5-Year Average | 11.7 | kr30.86 |
+36%
|
| Industry Average | 52 | kr137.08 |
+504%
|
| Country Average | 7.8 | kr20.45 |
-10%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| NO |
V
|
Vistin Pharma ASA
OSE:VISTN
|
1B NOK | 8.6 | 13.5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
853.2B USD | 28 | 41.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
544.6B USD | 16.6 | 25.9 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 11.6 | 19.6 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
225.8B GBP | 16.2 | 29.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
226.8B CHF | 12.4 | 20 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
278.5B USD | 9.5 | 15.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 386.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 7.9 | 10.7 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
155.3B USD | 7.7 | 20 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119.6B USD | 7.2 | 17 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 2.2 |
| Median | 7.8 |
| 70th Percentile | 16.6 |
| Max | 40 612.5 |
Other Multiples
Vistin Pharma ASA
Glance View
Vistin Pharma ASA engages in the manufacture and sale of metformin products. The company is headquartered in Oslo, Oslo. The company went IPO on 2015-06-10. The company was created as a result of spin-off of Weifa AS. The company specializes in manufacture of Active Pharmaceutical Ingredients (API) and Solid Dosage Forms. Its products portfolio is comprised of Metformin, Pholcodine and Codeine Phosphate, among others. The firm's products are sold domestically and abroad, including markets in Asia, America, Africa and Europe.
